Miller, David Scott <br/><br/>
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.  [electronic resource] 

 -  Cancer  Oct 2003 
 - 1664-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.11690  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Topotecan--administration & dosage